Am J Transplant, Volume 21, Suppl 3 Archives - Page 131 of 139 - ATC Abstracts

2021 American Transplant Congress
Summary of the OPTN’s Policy and System Modifications in Response to the COVID-19 Pandemic
A. Wilk, S. Taranto, C. Jett, L. Cartwright
UNOS, Richmond, VA
*Purpose: In April 2020, the OPTN made several policy and system modifications in response to the growing COVID-19 pandemic including updates to candidate lab data,…
2021 American Transplant Congress
Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients
L. Hasan¹, H. Hardgrave², T. Osborn³, R. Dare¹, L. Burdine⁴, E. Giorgakis⁴, J. Rico¹
¹Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Transplant surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: The FDA has issued Emergency Use Authorization (EUA) for monoclonal antibodies for the treatment of mild to moderate COVID-19 in patients at risk for…
2021 American Transplant Congress
Myeloid Foxo1-β-catenin Axis Regulates Hedgehog/Gli1 Signaling and Controls NLRP3-Mediated Innate Immune Responses in Sterile Inflammatory Liver Injury
D. Xu, C. Li, M. Sheng, Y. Lin, Y. Tian, Y. Zhan, A. J. Coito, R. W. Busuttil, D. G. Farmer, J. W. Kupiec-Weglinski, B. Ke
Surgery, Dumont - UCLA Transplant Center, Los Angeles, CA
*Purpose: Foxo1 plays important roles in cell metabolism, oxidative stress, inflammation, and apoptosis. Activation of Hedgehog/Gli1 signaling regulates cell growth, differentiation, and immune function. However,…
2021 American Transplant Congress
Systematic Screening of Kidney Transplant Patients Points Towards Deficits in Neutralizing Antibody Capacity Against Sars-cov-2
V. Wijtvliet¹, K. K. Ariën², J. Mariën², B. Peeters³, R. Hellemans⁴, A. Massart⁴, S. Van Hees¹, P. Moons⁵, H. Theeten⁶, P. Van Damme⁶, H. Goossens⁷, B. Y. De Winter¹, K. J. Ledeganck¹, D. Abramowicz⁴
¹Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium, ²Department of Biomedical Sciences, Institute of Tropical Medicine and University of Antwerp, Antwerp, Belgium, ³Department of Laboratory Medicine, Antwerp University Hospital, Antwerp, Belgium, ⁴Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium, ⁵Biobank, Antwerp University Hospital, Antwerp, Belgium, ⁶Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium, ⁷Department of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
*Purpose: The majority of kidney transplant recipients (KTR) is able to develop SARS-CoV-2 antibodies (Abs). Little is known about the virus neutralizing capacity of these…
2021 American Transplant Congress
Impact of Advanced Renal Dysfunction on Post-Transplant Outcomes After Living Donor Liver Transplantation in the United States
T. Bittermann¹, N. Kaur², P. L. Abt¹, K. M. Olthoff¹, J. K. Heimbach³, J. Emamaullee²
¹University of Pennsylvania, Philadelphia, PA, ²University of Southern California, Los Angeles, CA, ³Mayo Clinic College of Medicine, Rochester, MN
*Purpose: Survival after living donor liver transplantation (LDLT) in the U.S. is excellent. However, the significance of pre-transplant kidney disease on outcomes after LDLT is…
2021 American Transplant Congress
Evaluation and Experience with Hepatitis C Positive to Negative PancreasTransplantation
B. K. Lindner, B. Thomas, M. Cooper, S. Yi, P. Abrams
Medstar Georgetown University Hospital, Washington, DC
*Purpose: The use of hepatitis C virus (HCV) positive organs for transplant to HCV negative recipients has been reported on and has gained popularity across…
2021 American Transplant Congress
Insulin Secretion and Insulin Resistance Trajectories Over 1 Year After Kidney Transplantation: A Multicenter Prospective Cohort Study
B. Jun Bae, C. Oh
Department of Surgery, Ajou University Medical School, Suwon, Korea, Republic of
*Purpose: We investigated the changing patterns of insulin secretion and resistance and risk factors contributing to the development of post-transplant diabetes mellitus (PTDM) in kidney…
2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh¹, F. Messner², Y. Guo¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2021 American Transplant Congress
Management of Drug Interactions During Protocolized Implementation of Posaconazole Immediately Post Heart Transplant
G. Waldman, C. Rogers Marks, J. Clark, A. Woo, L. Irwin, A. Gerlach, G. D. Lewis, J. A. Fishman
Massachusetts General Hospital, Boston, MA
*Purpose: Posaconazole (POSA) is a strong CYP3A4 inhibitor known to increase tacrolimus exposure by up to 4-fold. Initiation requires empiric tacrolimus dose adjustment and close…